Hydrocortisone rapidly and significantly reduces the IL-6 level in blood and lungs of patients with COVID-19-related ARDS
Crit Care
.
2024 Mar 28;28(1):101.
doi: 10.1186/s13054-024-04887-2.
Authors
Antoine Guillon
1
2
,
Youenn Jouan
3
4
,
Arthur Kassa-Sombo
3
,
Christophe Paget
3
,
Pierre-François Dequin
5
3
Affiliations
1
Intensive Care Unit, Tours University Hospital, 2 Bd Tonnellé, 37044, Tours Cedex 9, France. antoine.guillon@univ-tours.fr.
2
Research Center for Respiratory Diseases, INSERM U1100, University of Tours, Tours, France. antoine.guillon@univ-tours.fr.
3
Research Center for Respiratory Diseases, INSERM U1100, University of Tours, Tours, France.
4
Cardiac Surgery Department, Tours University Hospital, Tours, France.
5
Intensive Care Unit, Tours University Hospital, 2 Bd Tonnellé, 37044, Tours Cedex 9, France.
PMID:
38549157
PMCID:
PMC10976785
DOI:
10.1186/s13054-024-04887-2
No abstract available
Publication types
Letter
MeSH terms
COVID-19* / complications
Humans
Hydrocortisone / therapeutic use
Interleukin-6
Lung
Respiratory Distress Syndrome* / drug therapy
Substances
Interleukin-6
Hydrocortisone